Epidermal Growth Factor in the Brain: A Promising Biomarker for Depression

Short title: Epidermal Growth Factor and Depression

Shu-xian Xu, M.D. & Ph.D.[1†]; Honggang Lyu, M.D.[1†]; Mian-mian Chen, M.D.[1]; Kun Li, M.D.[1]; Lihua Yao, M.D.[1]; Chao Wang, M.D. & Ph.D.[1]; Xin-hui Xie, M.D. & Ph.D.[1]*; Zhongchun Liu, M.D. & Ph.D.[1,2]*

Affiliations:

1. Department of Psychiatry, Renmin Hospital of Wuhan University, Wuhan, Hubei, PR China

2. Taikang center for life and medical sciences, Wuhan University, Wuhan, PR China

[†]These authors have contributed equally to this work.

*Corresponding authors:

Zhongchun Liu: Address: 1) Department of Psychiatry, Renmin Hospital of Wuhan University, No. 99 Jiefang Road, Wuchang District, Wuhan, Hubei, PR China. ZIP: 430060. Telephone: 86-8804191181399. 2) Taikang center for life and medical sciences, Wuhan University, Wuhan, PR China. ZIP: 430071. E-mail: zcliu6@whu.edu.cn

Xin-hui Xie: Address: 1) Department of Psychiatry, Renmin Hospital of Wuhan University, No. 99 Jiefang Road, Wuchang District, Wuhan, Hubei, PR China. ZIP:

430060. Telephone: 86-8804191181399. E-mail: xxh.med@gmail.com

Abstract

Background: This study aimed to examine the neurotrophic factors secreted from brain in depression by analyzing astrocyte-derived extracellular vesicles (ADEVs) isolated from plasma, and to explore the causal relationship between the expression of neurotrophic factors in the brain and depression.

Methods: A total of 40 patients with treatment-resistant depression (TRD) and 35 matched healthy controls (HCs) were recruited at baseline, and 34 TRD patients completed the post-electroconvulsive therapy (ECT) visits. The concentrations of five neurotrophic factors in ADEVs were measured. A correlation analysis was performed between neurotrophic factors in ADEVs and neurogenesis marker doublecortin (DCX) in neuron-derived extracellular vesicles (NDEVs). Subsequently, Mendelian randomization (MR) study and cell experiments were conducted.

Results: Our findings revealed a decrease in the level of epidermal growth factor (EGF) in ADEVs among TRD patients, with an increase observed post-ECT. The corrected area under the curve for EGF were larger than those for other neurotrophic factors: 0.99 (95% CI: 0.98-1.00). MR suggested that decreased expression levels of the *EGF* gene in the cortex constitute a risk factor for depression**.** We observed a positive correlation between the levels of EGF in ADEVs and DCX in NDEVs. Subsequently, cell experiments suggested that EGF can activate EGF receptor (EGFR) to trigger the PI3K-Akt pathway, participating in the promotion of DCX.

Conclusions: This study provides the *in vivo* evidences supporting that a reduction in EGF levels in the central nervous system could potentially contribute to depression

and serve as a biomarker for it. Additionally, the EGF/EGFR signaling pathway may be involved in regulating early neurogenesis traits in depression.

Keywords: treatment-resistant depression; neurotrophic factors; astrocyte-derived extracellular vesicle; neurogenesis; Mendelian randomization

Introduction

Major depressive disorder (MDD) is among the most prevalent mental disorders, marked by significant and enduring depression, loss of interest, and anhedonia[1,2]. It is also a leading cause of disability worldwide and contributes substantially to the global burden of disease[3].

Various hypotheses have been proposed to explain the underlying causes of depression[4,5]. Among them, the neurotrophic hypothesis of depression suggests that MDD-related synaptic and brain changes are primarily due to disrupted neurotrophic support[5]. Neurotrophic factors are of major importance because it modulates the plasticity and neurogenesis, inhibits cell death cascades and increases cell survival proteins that are responsible for proliferation and maintenance of central nervous system (CNS) neurons[4,6].

Astrocytes, known for their critical role in regulating neurotrophic factors and gliotransmitters that maintain brain homeostasis[7,8], may potentially contribute to the neuropathology of depression[9,10]. Astrocytes produce various neurotrophic factors, including brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), epidermal growth factor (EGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF-1), vascular endothelial growth factor (VEGF), and nerve growth factor (NGF), all of which are implicated in the etiology and treatment of depression[11,12]. Among them, EGF is a protein that could be valuable for the early diagnosis and treatment assessment of depression. For instance, MDD patients with the rs11569017-TT genotype showed low plasma levels of EGF when

compared to controls[13]. MDD patients exhibit reduced EGF receptor *ErbB3* expression, which increases and correlates with clinical improvement following 12 weeks of antidepressant treatment [14]. This suggests that investigating variations in the *EGF* gene and their receptor expression could serve as a clinical predictor of recovery in depression.

Unfortunately, research on other neurotrophic factors in depression remains limited, with inconsistent findings. Peripheral blood samples, used in many previous studies[15], might not accurately reflect brain neurotrophic factor levels due to their widespread expression in various tissues[16-18]. Investigating these factors directly within the brain is likely crucial for a deeper understanding of depression. The difficulty of directly measuring neurotrophic factor levels in the CNS hinders the acquisition of *in vivo* molecular evidence in patients with MDD. However, recent breakthroughs in isolating brain-derived extracellular vesicles (EVs) offer a revolutionary non-invasive approach for assessing CNS status *in vivo*. These EVs hold immense promise as a "liquid biopsy" to evaluate molecular alterations within the brain[19-21].

In this study, we initially found a decrease in the level of EGF in astrocyte-derived extracellular vesicles (ADEVs) among treatment-resistant depression (TRD) patients compared to controls, with an increase observed post-electroconvulsive therapy (ECT). Subsequently, a Mendelian randomization (MR) study was conducted to explore the causal effect of *EGF/EGF receptor (EGFR)* gene expression on depression from a genetic perspective. As we also observed a positive

correlation between EGF levels in ADEVs and the early neurogenesis marker doublecortin (DCX) in neuron-derived extracellular vesicles (NDEVs). Cell experiments using SH-SY5Y cells were then performed to investigate the relationship between EGF and DCX.

Methods

Participants details

This observational longitudinal cohort was conducted at Renmin Hospital of Wuhan University in accordance with the Declaration of Helsinki[22] as our previous study[23,24]. The Human Ethics Committee approved the study protocol. Patients or their legal guardians provided informed consents. This report follows the STrengthening the Reporting of Observational studies in Epidemiology (STROBE) statement[25].

A total of 40 patients with TRD and 35 age-, and sex-matched healthy controls (HCs) were recruited. Subjects were excluded if they had comorbidity with other major psychiatric disorders. The HCs were required to be in good physical health, with no personal or first-degree family history of psychiatric disorders.

Thirty-four patients with TRD completed the post-ECT visits. Six milliliters of blood were drawn at baseline (T1), and 24 hours after the final ECT session (T2) to mitigate acute treatment effects. Cohort details and ECT procedures can be found in supplementary materials and our previous studies[23,24].

Isolation and confirmation of ADEVs

119 We employed different isolation methods for ADEVs used in protein measurements
120 and cell treatments. A two-step ADEVs protocol based on our prior work[24] was used
121 for protein analysis. In contrast, ADEVs for cell treatment underwent
122 ultracentrifugation (UC)[26] to isolate the total plasma EVs, followed by the same
123 immunoprecipitation method to isolate ADEVs. This approach avoided potential
124 contamination and cellular effects associated with polymer precipitation methods
125 commonly used in clinical settings. Confirmation of ADEV isolation was performed
126 using transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA),
127 and western blotting. Please refer to the supplementary materials and our previous
128 studies[24] for more details.
129

130 **Protein measurements in ADEVs**

131 The levels of CD81, an EV marker, was measured using enzyme-linked
132 immunosorbent assay (ELISA) kit (American Research Products Inc., Catalog#
133 CSB-EL004960HU). Neurotrophic factors BDNF, FGF-2, GDNF, EGF and NGF-β in
134 ADEVs were measured using 5-Plex Human ProcartaPlex™ Panel (Thermo Fisher
135 Scientific).
136

137 **Causal genetic evidence from Mendelian randomization**

138 A MR study was conducted to validate the association between the neurotrophic
139 factors identified above and depression from a genetic perspective. By utilizing
140 genetic variants as instrumental variables, MR can provide more robust causal

141 inference between exposures and outcomes compared to traditional observational
142 studies, thereby mitigating common confounding factors such as residual confounding,
143 reverse causation bias, and measurement error. In this study, we leveraged brain-tissue
144 specific expression quantitative trait loci (eQTL) data and genome-wide association
145 study (GWAS) summary statistics on depression to perform two-sample MR (**sFigure**
146 **1**). Wald ratio and inverse variance weighting (IVW) were employed as the primary
147 analytical methods in the main analysis. Additionally, sensitivity analyses were
148 conducted. Details are provided in the supplementary materials.
149

150 **Culture and treatments of SH-SY5Y cells**

151 The SH-SY5Y cell line was obtained from Wuhan Procell Biotech Co., Ltd., China.
152 These cells were cultured in basic DMEM/F-12 medium (Gibco, Catalog#
153 C11330500BT) supplemented with 10% fetal bovine serum (FBS, WISENT, Catalog#
154 086-150) and 100 U/ml Penicillin-Streptomycin (Gibco, Catalog# 15140122) under
155 5% CO_2 at 37 °C. The medium was changed every 2-3 days, and when the cell density
156 reached 80-90%, they were passaged at a 1:3 ratio.

157 Next, the well-growing SH-SY5Y cells were seeded in a 6-well plate at a density
158 of 6 $*10^5$ cells per well with 2.5 ml medium for 24 hours. All cells used in the
159 experiment were in the logarithmic growth phase. The cells were divided into two
160 groups: the HC group (treated with ADEVs from 6 HCs) and the TRD group (treated
161 with ADEVs from 6 patients with TRD). The EGF levels in ADEVs from HCs were
162 higher than those in TRD. ADEVs were diluted with culture medium to a final

concentration of 20 μg/ml. After incubating with the respective agents for 24 hours, the cells were harvested for subsequent analysis.

Furthermore, we performed another experiment, the well-growing SH-SY5Y cells were seeded in a 6-well plate at a density of 6 $*10^5$ cells per well with 2.5 ml medium for 24 hours. All cells used in the experiment were in the logarithmic growth phase. Recombinant human EGF protein was diluted to a final concentration of 10 ng/ml to treat SH-SY5Y cells. The control group received an equal volume of growth medium instead of the EGF solution. After 24 hours of treatment, the cells were harvested for analysis.

Western blotting

Previous studies found that EGF binds to its receptor EGFR, activating the PI3K-Akt and MAPK-Erk pathways which are crucial for neurogenesis in depression[27-29]. Therefore, we analyzed the proteins in these two pathways.

The following proteins were detected in SH-SY5Y cells: DCX (Abcam, Catalog# ab207175), GAPDH (Huabio, Catalog# HA721131), EGFR (Affinity, Catalog# AF6043), Phospho-EGFR (Tyr1068) (Affinity, Catalog# AF3045), Akt (Cell Signaling, Catalog# 9272S), Phospho-Akt (Ser473) (Cell Signaling, Catalog# 4060S), PI3K p85 (Affinity, Catalog# AF6241), Phospho-PI3K p85 (Affinity, Catalog# AF3241), Erk1/2 (Cell Signaling, Catalog# 9102S), Phospho-Erk1/2 (Thr202/Tyr204) (Cell Signaling, Catalog# 4370T).

185 **Statistical analyses**

186 For the clinical data, in the main analysis of protein levels in ADEVs at baseline,
187 following the MIESV 2018[30], the outcomes were defined as the ratio of protein
188 concentrations to CD 81 concentrations. General linear models (GLMs) were used to
189 examine differences between two groups. In the GLMs, we set the outcomes as
190 dependent variables and group as the independent variable, while controlling for
191 covariates for sex and age. To represent the differences between the two groups, we
192 used model-fitted estimated marginal means (EMMs) and their corresponding 95%
193 confidence intervals (CIs). Additionally, to ensure robustness, a sensitivity analysis
194 was conducted, with protein concentration levels per 1 ml plasma set as dependent
195 variables. Receiver operating characteristic curves (ROCs) and corrected area under
196 the curve (AUC) were employed to further explore the potential of these neurotrophic
197 factors in ADEVs as biomarkers. In the exploratory analysis, Spearman coefficient
198 was used to examine the correlation between EGF in ADEVs and DCX in NDEVs (as
199 reported in our previous report[23]). For the comparisons between pre- and post-ECTs
200 (paired longitudinal data), paired *t*-tests were used, with Cohen's *d* and its associated
201 95% CIs utilized to quantify effect sizes. Similar to the comparisons at baseline, a
202 sensitivity analysis was conducted with the concentrations of protein levels per 1 ml
203 plasma as dependent variables. False discovery rate (FDR) correction (Benjamini and
204 Hochberg method) was employed to mitigate false positive outcomes. In comparisons
205 of data from cell experiments, the Wilcoxon tests were employed. A two-tailed
206 *p*-values less than 0.05 was considered significant. All statistical analyses were

performed using R version 4.1.0 (R Project for Statistical Computing) within Rstudio version 1.4.1106 (Rstudio).

Results

EGF levels in ADEVs represent a promising potential biomarker for depression

Among 40 patients with TRD, six patients either did not undergo ECT treatment or did not complete the post-ECT visit. Detailed baseline characteristics of the participants was provided in **sTable 1**.

At baseline, the level of EGF in the TRD group was significantly lower than in the HC group. This effect was consistent across different normalization methods. Changes in other neurotrophic factors were more variable and yielded different outcomes depending on the normalization method used (**Table 1** and **Figure 1**). The AUCs for EGF were larger than those for other neurotrophic factors, with values of 0.99 (95% CI: 0.98-1.00) and 0.93 (95% CI: 0.86-0.99), respectively (**Figure 1**). This indicates that EGF in ADEVs has a strong discrimination ability. Additionally, the EGF level in ADEVs showed a positive correlation (ρ = 0.38, p < 0.001) with the DCX level in NDEVs (**sFigure 2**).

Following ECT, there was a significant increase in EGF levels, this effect was also consistent across different normalization methods (**Table 2** and **Figure 2**). In summary, among the five neurotrophic factors tested, EGF showed the most robust results both at baseline and in terms of changes before and after ECT.

229 **Causal influence of brain-specific *EGF* gene expression on depression**

230 Given the significant correlation between EGF expression and depression above, we
231 employed MR to investigate the causal influence of brain-tissue specific *EGF* and
232 *EGFR* genes expression on depression. Adhering to MR assumptions, we identified
233 cis-eQTL data for *EGF* and *EGFR* genes in the brain cortex, respectively (**sTable 2**).
234 Our MR analysis suggests that decreased expression of the *EGF* gene in the cortex
235 may be a potential risk factor for depression (Wald ratio OR= 0.95, p = 0.009)
236 (**sFigure 3**). However, neither method found a significant causal relationship between
237 *EGFR* and depression.

238 Subsequently, we attempted to identify potential mechanistic pathways between
239 *EGF/EGFR* genes and depression through MELODI Presto[31]. The analysis revealed
240 that potential intermediary factors between these genes and depression were primarily
241 associated with metabolic processes, cellular function, and neurological disorders.
242 Interestingly, the results suggest an overlap between the *EGF*-depression interaction
243 and the serotonin transporter pathway, potentially implicating *EGF* as a target for
244 antidepressant development (**sTable 3**).

245

246 **EGF activates EGFR to participate in the promotion of DCX expression**

247 ADEVs purified using UC were confirmed via TEM, NTA, and western blotting
248 validating successful ADEVs collection (**sFigure 4**).

249 As shown in **Figure 3A-F**, after 24 hours of intervention with ADEVs from
250 patients with TRD and HCs, the expression level of the DCX protein in SH-SY5Y

cells intervened by ADEVs in the HC group showed a significant increase compared to the TRD group (p = 0.009). Moreover, there was a significant increase in the phosphorylation level of the EGFR (p = 0.041), along with simultaneous increases in the phosphorylation levels of downstream pathway proteins PI3K (p = 0.004) and Akt (p = 0.015). However, there was no significant difference in the phosphorylation level of Erk between the two groups (p = 0.818).

Following a 24-hour intervention with recombinant human EGF (**Figure 3G-L**), the expression level of the DCX protein in SH-SY5Y cells significantly increased compared to the control group (p = 0.041), accompanied by a significant elevation in the phosphorylation level of EGFR (p = 0.015). Furthermore, the phosphorylation levels of downstream pathway proteins PI3K (p = 0.015) and Akt (p = 0.004) were also significantly increased concurrently. Nonetheless, there was no significant difference in the phosphorylation level of Erk between the two groups (p = 0.240).

Discussion

Our study, using plasma ADEVs, indicates that decreased levels of EGF in the CNS could serve as a biomarker for depression. Subsequently, MR results suggest that decreased expression of the *EGF* gene in the cortex may contribute to the development of depression. We also discovered a positive correlation between EGF levels in ADEVs and DCX, suggesting that the EGF/EGFR signaling pathway may play a role in regulating early neurogenesis traits in depression.

This study's strength lies in directly acquiring CNS evidences through ADEVs

273 and MR based on brain-tissue data, bypassing limitations of peripheral sources.
274 Neurotrophic factors, like EGF, are often found at higher levels in peripheral tissues
275 compared to the brain[17,18]. This widespread expression can confound results when
276 solely using peripheral measures, a common limitation in depression studies.
277 Additionally, the blood-brain barrier further complicates assessing CNS neurotrophic
278 factors[32]. Therefore, our study offered valuable insights into the brain-specific
279 relationship between neurotrophic factors and depression.
280

281 **EGF and depression**

282 Previous research on EGF and depression has yielded conflicting results. While
283 one study found elevated EGF levels in adolescents with depression or bipolar
284 disorder[33], another study focusing on elderly patients did not detect differences
285 compared to HCs[34], consistent with another case-control study[35]. Additionally, two
286 studies reported decreased peripheral blood EGF levels in depressed patients[13,36],
287 consistent with findings of downregulated *EGF* mRNA levels in peripheral blood[37].
288 Additionally, cognitive alterations in MDD patients have been associated with the
289 SNP rs2250724 of *EGF* gene[38].

290 Heterogeneity in EGF findings likely stems from several factors. First, variations
291 in study populations can influence results. Serum EGF levels demonstrably decline
292 with age[39], highlighting potential age-related heterogeneity. Second, comorbid
293 conditions like anxiety might confound EGF expression. A study reported elevated
294 EGF in patients with mild to moderate depression and anxiety[40], while others found

295 decreases in depression without anxiety[13,36]. Most importantly, previous research has
296 primarily focused on assessing EGF levels in peripheral blood, where they can be
297 influenced by various tissues[17]. This highlights the importance of directly assessing
298 EGF expression within the CNS, precisely the approach employed in our study. We
299 utilized ADEVs for the first time to detect EGF within the brains of depression
300 patients, and observed a significant decrease in EGF levels in TRD patients compared
301 to HCs. ROC curve analyses revealed high sensitivity and specificity of EGF in
302 ADEVs in identifying TRD, suggesting it as a promising biomarker for depression.

303 Our study further revealed that levels of EGF in ADEVs increased following
304 ECTs in patients with depression. Earlier studies have observed acute changes in EGF
305 levels after ECT. For example, one study reported a significant decrease in serum
306 EGF concentrations following ECTs[41], while another focusing on schizophrenia
307 showed no change in serum EGF levels between antipsychotic therapy alone and
308 combined ECT and antipsychotic treatment[42]. Notably, these prior studies relied on
309 peripheral EGF measurements, which may not reflect central EGF dynamics.
310 However, our findings, based on ADEVs which directly reflect the CNS, suggest EGF
311 as a potential marker for ECT response, highlighting the importance of CNS-level
312 assessment for understanding and treating depression.

313 Additionally, our MR analysis indicated that genetically predicted decreases in
314 *EGF* gene expression constitute a potential risk factor for depression, further
315 supporting our clinical observations. As eQTL effects on gene expression can vary
316 depending on the tissue examined, potentially introducing confounding factors and

leading to incorrect inferences. To address this limitation, we specifically investigated the causal relationship between *EGF* eQTLs derived from brain-tissue specifically in the cortex and depression. To strengthen our results, we used the MELODI Presto analysis tool to further prioritize the *EGF* gene, highlighting its potential interactions with antidepressive agents. This provides additional evidence supporting the involvement of *EGF* in the mechanisms of antidepressant activity. This approach offers insights into the biological pathways linking *EGF* and depression, indicating that changes in the *EGF* expression could play a crucial role in the pathogenesis of depression.

The observed genetic associations with reduced *EGF* expression reinforce the need for additional preclinical studies to investigate how *EGF*-based interventions might benefit patients with depression, and they also shed light on how *EGF*-related pathways contribute to the onset and treatment of depression.

EGF/EGFR, neurogenesis and depression

Our previous study using NDEVs, firstly provided human *in vivo* evidence of reduced markers of early neurogenesis DCX in patients with TRD, and observed increased traits of immature neurons following ECT[23]. One potential mechanism linking neurogenesis impairments with depression is through the loss of neurotrophic factors and the disruption of their associated signaling pathways[5]. This study discovered a notable positive correlation between EGF levels in ADEVs and DCX levels in NDEVs. This finding suggests a potential link between EGF and early

339 neurogenesis. Then, we validated that ADEVs from HCs, with higher EGF levels,
340 increased DCX expression in SH-SY5Y cells compared to ADEVs from patients with
341 TRD. Similarly, EGF protein alone also stimulated DCX expression in SH-SY5Y
342 cells, potentially via the EGFR-PI3K-Akt pathway.

343 Astrocytes are the predominant cell type within the neurogenic niche, creating a
344 specialized environment for neurogenesis[43]. Previous studies have found that
345 astrocytes can secret EGF to increase neurogenesis[8,44]. EGF can promotes the
346 differentiation, maturation, and survival of various neurons, exerting neuromodulatory
347 effects on different types of neurons in the CNS[44]. The exogenous EGF has specific
348 effects on precursor cells *in vivo*[45]. Administering EGF into the ventricles for 2 weeks
349 expands precursor cell populations in the subventricular zone (SVZ), decreases the
350 total number of newborn neurons reaching the olfactory bulb, and significantly
351 increases the production of olfactory bulb astrocytes. Moreover, EGF increases the
352 number of newborn cells in the striatum either by migrating SVZ cells or by
353 stimulating local precursor cells, while also boosting the number of newborn glial
354 cells and reducing newborn neurons[46]. These findings illuminate EGF's role in
355 neurogenesis, and emerging evidence suggests that neurogenesis may play a role in
356 depression[47].

357 However, there is limited research exploring the relationship between EGF and
358 neurogenesis in depression. One study shown that FGF, EGF, BDNF, ketamine,
359 melatonin and the ketamine/melatonin combination stimulate neurogenesis and cell
360 cluster formation in cultured human olfactory neuronal precursors, thus offering

361 insights into the mechanism underlying their antidepressant effects[48]. Once EGF binds
362 to its receptor, EGFR, it forms a homodimer, which undergoes autophosphorylation in
363 the intracellular kinase domain, activating signaling cascades within the cell and even
364 in the nucleus[49]. Upon EGFR activation, the main downstream signaling pathways
365 include the PI3K-Akt pathway, the Ras-Raf-MAPK-Erk pathway, and the JAK/STAT
366 signaling pathway[29]. Studies have shown that the PI3K-Akt and MAPK-Erk signaling
367 pathways play crucial roles in neurogenesis, with several therapeutic targets for
368 depression acting on these pathways to promote neuronal growth and survival[27,28].
369 Our findings suggest that EGF might exert its effect on early neurogenesis in
370 depression by specifically activating the EGFR, which in turn triggers the PI3K-Akt
371 pathway. This activation pattern contrasts with the MAPK-Erk pathway, often
372 implicated in other cell growth and differentiation processes, indicating that the
373 selective activation of PI3K-Akt by EGF could be a distinctive mechanism through
374 which early neurogenesis is influenced in the context of depression. ECT may
375 stimulate this signaling pathway by promoting EGF secretion, leading to increased
376 early neurogenesis and potentially achieving antidepressant effects.
377

378 **EV, a candidate key mediator in mediating EGF-neurogesis signaling**

379 During the process of EGF/EGFR signaling, EVs may play a significant role.
380 EVs derived from neurons and neuroglial cells exert crucial bidirectional regulatory
381 effects in the physiological and pathological processes of the CNS[50]. These nanoscale
382 messengers not only ferry information from neurons to glial cells but also mediate the

383 reverse pathway, influencing neuronal function and establishing a dynamic
384 intercellular network[20]. For instance, neurons can transfer miR-124b to astrocytes via
385 EVs, enhancing the expression of glutamate transporter-1 in astrocytes, thereby
386 regulating synaptic plasticity[51]. Additionally, ADEVs can enhance neuronal survival
387 under ischemic and hypoxic conditions by delivering antiviral proteins[52]. Regarding
388 our study, results of cell experiments suggest a possible antidepressant mechanism
389 between astrocytes and neurogenesis, EGF carried by ADEVs activates the EGFR
390 signaling pathway (including PI3K-Akt) in neurons, thereby promoting neuronal
391 proliferation and growth.

392 This study proposes a novel framework for investigating CNS diseases in human
393 subjects. By leveraging brain-derived extracellular vesicles (BDEVs), we can gain
394 initial insights into the *in vivo* CNS state, facilitating the study of real-world
395 pathological conditions. Furthermore, complementing BDEV analysis with *in vitro*
396 cell experiments offers a comprehensive understanding of CNS biology. Additionally,
397 the potential of EVs as drug delivery vehicles, with their ability to cross the
398 blood-brain barrier and target specific cell types, opens exciting avenues for
399 developing targeted therapeutic strategies for CNS diseases.

400

401 **Limitations**

402 This study has several limitations. Firstly, the limited quantity of ADEVs restricted
403 high-throughput omics analyses, also hindering the detection of additional
404 neurotrophic factors. Additionally, plasma ADEVs represent the entire brain,

405 precluding identification of specific neurotrophic factor source regions. Elucidating
406 these regional origins is helpful for understanding their roles in depression. Secondly,
407 for the MR study, the major GWAS data populations were predominantly European,
408 necessitating further validation of these MR findings in other populations. Also, the
409 limited number of instruments for cis-eQTL data from cortex tissue and other brain
410 tissues to investigate their association with depression, warranting further examination
411 in future studies. Furthermore, large-scale independent tissue-specific eQTL datasets
412 and employing additional genetic methods like transcriptome-wide association
413 studies[53] to estimate gene expression effects on depression should be considered in
414 future studies. We look forward to future research addressing this issue more
415 specifically. Thirdly, for cell experiments, resource constraints necessitated using the
416 SH-SY5Y cell line instead of primary neural stem cells, potentially compromising the
417 accuracy of neurogenesis data. Future studies should prioritize neural stem cells for a
418 more faithful representation of neurogenesis processes. Additionally,
419 serum-containing media hindered precise control over EGF levels, potentially
420 influencing our results. Employing serum-free media would enhance experimental
421 control. Finally, the complex composition of ADEVs limited our ability to identify the
422 specific pro-neurogenic molecule(s). Future studies isolating and analyzing individual
423 ADEV components are necessary to pinpoint the molecules responsible for the
424 observed increase in neurogenesis.
425
426 **Conclusions**

This study provides *in vivo* evidence for a potential role of reduced CNS EGF levels in TRD patients, suggesting EGF as a promising biomarker. Then using MR, we revealed a causal influence of low brain-specific *EGF* gene expression on depression. Furthermore, our findings highlight the involvement of the EGF/EGFR signaling pathway in regulating early neurogenesis, a process implicated in depression. These insights may offer critical insights for developing novel antidepressant therapies targeting the EGF/EGFR pathway using EVs.

Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China (U21A20364). No funding was received from commercial organizations.

Conflict of interest disclosure

The authors declare no competing interests.

Authors' contributions

SXX conducted methodology, investigation, data curation, and contributed to the original draft and conceptualization. HL contributed to data curation and participated in manuscript review and editing. MMC and KL conducted investigation and data curation. LY and CW participated in manuscript review and editing. XHX provided conceptualization, performed formal analysis, visualization and supervision. ZL provided project administration, supervision, and acquired funding.

452 **References**

453 1. Otte C, Gold SM, Penninx BW, et al. Major depressive disorder. *Nat Rev Dis*
454 *Primers*. Sep 15 2016;2:16065. doi:10.1038/nrdp.2016.65

455 2. Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204
456 countries and territories, 1990-2019: a systematic analysis for the Global Burden of
457 Disease Study 2019. *Lancet*. Oct 17 2020;396(10258):1204-1222.
458 doi:10.1016/S0140-6736(20)30925-9

459 3. Friedrich MJ. Depression Is the Leading Cause of Disability Around the World.
460 *JAMA*. Apr 18 2017;317(15):1517. doi:10.1001/jama.2017.3826

461 4. Chopra K, Kumar B, Kuhad A. Pathobiological targets of depression. *Expert*
462 *Opin Ther Targets*. Apr 2011;15(4):379-400. doi:10.1517/14728222.2011.553603

463 5. Fries GR, Saldana VA, Finnstein J, Rein T. Molecular pathways of major
464 depressive disorder converge on the synapse. *Mol Psychiatry*. Jan 2023;28(1):284-297.
465 doi:10.1038/s41380-022-01806-1

466 6. Skaper SD. Neurotrophic Factors: An Overview. *Methods Mol Biol*.
467 2018;1727:1-17. doi:10.1007/978-1-4939-7571-6_1

468 7. Cope EC, Gould E. Adult Neurogenesis, Glia, and the Extracellular Matrix. *Cell*
469 *Stem Cell*. May 2 2019;24(5):690-705. doi:10.1016/j.stem.2019.03.023

470 8. Araki T, Ikegaya Y, Koyama R. The effects of microglia- and astrocyte-derived
471 factors on neurogenesis in health and disease. *Eur J Neurosci*. Sep
472 2021;54(5):5880-5901. doi:10.1111/ejn.14969

473 9. Wang Q, Jie W, Liu JH, Yang JM, Gao TM. An astroglial basis of major

474 depressive disorder? An overview. *Glia*. Aug 2017;65(8):1227-1250.
475 doi:10.1002/glia.23143
476 10. Rajkowska G, Stockmeier CA. Astrocyte pathology in major depressive disorder:
477 insights from human postmortem brain tissue. *Curr Drug Targets*. Oct
478 2013;14(11):1225-36. doi:10.2174/13894501113149990156
479 11. Galvez-Contreras AY, Campos-Ordonez T, Lopez-Virgen V, Gomez-Plascencia J,
480 Ramos-Zuniga R, Gonzalez-Perez O. Growth factors as clinical biomarkers of
481 prognosis and diagnosis in psychiatric disorders. *Cytokine Growth Factor Rev*. Dec
482 2016;32:85-96. doi:10.1016/j.cytogfr.2016.08.004
483 12. Martin JL, Magistretti PJ, Allaman I. Regulation of neurotrophic factors and
484 energy metabolism by antidepressants in astrocytes. *Curr Drug Targets*. Oct
485 2013;14(11):1308-21. doi:10.2174/1389450111314110009
486 13. Tian W, Zhang J, Zhang K, et al. A study of the functional significance of
487 epidermal growth factor in major depressive disorder. *Psychiatr Genet*. Aug
488 2012;22(4):161-7. doi:10.1097/YPG.0b013e3283539550
489 14. Milanesi E, Minelli A, Cattane N, et al. ErbB3 mRNA leukocyte levels as a
490 biomarker for major depressive disorder. *BMC Psychiatry*. Sep 18 2012;12:145.
491 doi:10.1186/1471-244X-12-145
492 15. Wang H, Yang Y, Pei G, Wang Z, Chen N. Neurotrophic basis to the pathogenesis
493 of depression and phytotherapy. *Front Pharmacol*. 2023;14:1182666.
494 doi:10.3389/fphar.2023.1182666
495 16. Colitti M. Distribution of BDNF and TrkB isoforms in growing antler tissues of

496 red deer. *Ann Anat*. Sep 2017;213:33-46. doi:10.1016/j.aanat.2017.05.007

497 17. Fukuyama R, Shimizu N. Expression of epidermal growth factor (EGF) and the
498 EGF receptor in human tissues. *J Exp Zool*. Jun 1991;258(3):336-43.
499 doi:10.1002/jez.1402580309

500 18. The Genotype-Tissue Expression (GTEx) Portal
501 https://www.gtexportal.org/home/.

502 19. Shi M, Sheng L, Stewart T, Zabetian CP, Zhang J. New windows into the brain:
503 Central nervous system-derived extracellular vesicles in blood. *Prog Neurobiol*. Apr
504 2019;175:96-106. doi:10.1016/j.pneurobio.2019.01.005

505 20. Saint-Pol J, Gosselet F, Duban-Deweer S, Pottiez G, Karamanos Y. Targeting and
506 Crossing the Blood-Brain Barrier with Extracellular Vesicles. *Cells*. Apr 1
507 2020;9(4)doi:10.3390/cells9040851

508 21. Brenna S, Krisp C, Altmeppen HC, Magnus T, Puig B. Brain-Derived
509 Extracellular Vesicles in Health and Disease: A Methodological Perspective. *Int J Mol*
510 *Sci*. Jan 29 2021;22(3)doi:10.3390/ijms22031365

511 22. World Medical A. World Medical Association Declaration of Helsinki: ethical
512 principles for medical research involving human subjects. *JAMA*. Nov 27
513 2013;310(20):2191-4. doi:10.1001/jama.2013.281053

514 23. Xie XH, Xu SX, Yao L, et al. Altered in vivo early neurogenesis traits in patients
515 with depression: Evidence from neuron-derived extracellular vesicles and
516 electroconvulsive therapy. *Brain Stimul*. Jan-Feb 2024;17(1):19-28.
517 doi:10.1016/j.brs.2023.12.006

518 24. Xu SX, Xie XH, Yao L, et al. Human in vivo evidence of reduced astrocyte
519 activation and neuroinflammation in patients with treatment-resistant depression
520 following electroconvulsive therapy. *Psychiatry Clin Neurosci*. Dec
521 2023;77(12):653-664. doi:10.1111/pcn.13596
522 25. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of
523 Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting
524 observational studies. *Lancet*. Oct 20 2007;370(9596):1453-7.
525 doi:10.1016/S0140-6736(07)61602-X
526 26. Greening DW, Xu R, Ji H, Tauro BJ, Simpson RJ. A protocol for exosome
527 isolation and characterization: evaluation of ultracentrifugation, density-gradient
528 separation, and immunoaffinity capture methods. *Methods Mol Biol*.
529 2015;1295:179-209. doi:10.1007/978-1-4939-2550-6_15
530 27. Liu Q, Zhang J, Xiao C, et al. Akebia saponin D protects hippocampal
531 neurogenesis from microglia-mediated inflammation and ameliorates depressive-like
532 behaviors and cognitive impairment in mice through the PI3K-Akt pathway. *Front*
533 *Pharmacol*. 2022;13:927419. doi:10.3389/fphar.2022.927419
534 28. Xia CX, Gao AX, Dong TT, Tsim KW. Flavonoids from Seabuckthorn
535 (Hippophae rhamnoides L.) mimic neurotrophic functions in inducing neurite
536 outgrowth in cultured neurons: Signaling via PI3K/Akt and ERK pathways.
537 *Phytomedicine*. Jul 2023;115:154832. doi:10.1016/j.phymed.2023.154832
538 29. Wee P, Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling
539 Pathways. *Cancers (Basel)*. May 17 2017;9(5)doi:10.3390/cancers9050052

540 30. Thery C, Witwer KW, Aikawa E, et al. Minimal information for studies of
541 extracellular vesicles 2018 (MISEV2018): a position statement of the International
542 Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *J*
543 *Extracell Vesicles*. 2018;7(1):1535750. doi:10.1080/20013078.2018.1535750
544 31. Elsworth B, Gaunt TR. MELODI Presto: a fast and agile tool to explore semantic
545 triples derived from biomedical literature. *Bioinformatics*. May 1 2021;37(4):583-585.
546 doi:10.1093/bioinformatics/btaa726
547 32. Thorne RG, Frey WH, 2nd. Delivery of neurotrophic factors to the central
548 nervous system: pharmacokinetic considerations. *Clin Pharmacokinet*.
549 2001;40(12):907-46. doi:10.2165/00003088-200140120-00003
550 33. Skibinska M, Kapelski P, Dmitrzak-Weglarz M, et al. Elevated Epidermal Growth
551 Factor (EGF) as Candidate Biomarker of Mood Disorders-Longitudinal Study in
552 Adolescent and Young Adult Patients. *J Clin Med*. Sep 8
553 2021;10(18)doi:10.3390/jcm10184064
554 34. Wu HE, Teixeira AL, Barroso L, et al. Epidermal growth factor and fibroblast
555 growth factor-2 circulating levels in elderly with major depressive disorder.
556 *Psychiatry Res*. Feb 2019;272:141-143. doi:10.1016/j.psychres.2018.12.084
557 35. Domenici E, Wille DR, Tozzi F, et al. Plasma protein biomarkers for depression
558 and schizophrenia by multi analyte profiling of case-control collections. *PLoS One*.
559 Feb 11 2010;5(2):e9166. doi:10.1371/journal.pone.0009166
560 36. Sohan M, Qusar M, Shahriar M, Islam SMA, Bhuiyan MA, Islam MR.
561 Association of reduced serum EGF and leptin levels with the pathophysiology of

562 major depressive disorder: A case-control study. *PLoS One*. 2023;18(7):e0288159.
563 doi:10.1371/journal.pone.0288159
564 37. Woo HI, Lim SW, Myung W, Kim DK, Lee SY. Differentially expressed genes
565 related to major depressive disorder and antidepressant response: genome-wide gene
566 expression analysis. *Exp Mol Med*. Aug 3 2018;50(8):1-11.
567 doi:10.1038/s12276-018-0123-0
568 38. Tian WM, Zhang KR, Zhang J, Shen Y, Xu Q. Association between the epidermal
569 growth factor gene and intelligence in major depression patients. *Chin Med Sci J*. Jun
570 2010;25(2):105-8. doi:10.1016/s1001-9294(10)60031-4
571 39. Kjaer IM, Olsen DA, Alnor A, Brandslund I, Bechmann T, Madsen JS. EGFR and
572 EGFR ligands in serum in healthy women; reference intervals and age dependency.
573 *Clin Chem Lab Med*. Nov 26 2019;57(12):1948-1955. doi:10.1515/cclm-2019-0376
574 40. Memon AA, Sundquist K, Ahmad A, Wang X, Hedelius A, Sundquist J. Role of
575 IL-8, CRP and epidermal growth factor in depression and anxiety patients treated with
576 mindfulness-based therapy or cognitive behavioral therapy in primary health care.
577 *Psychiatry Res*. Aug 2017;254:311-316. doi:10.1016/j.psychres.2017.05.012
578 41. Stelzhammer V, Guest PC, Rothermundt M, et al. Electroconvulsive therapy
579 exerts mainly acute molecular changes in serum of major depressive disorder patients.
580 *Eur Neuropsychopharmacol*. Oct 2013;23(10):1199-207.
581 doi:10.1016/j.euroneuro.2012.10.012
582 42. Zhang X, Xiao W, Chen K, et al. Serum Epidermal Growth Factor is Low in
583 Schizophrenia and Not Affected by Antipsychotics Alone or Combined With

584 Electroconvulsive Therapy. *Front Psychiatry*. 2020;11:104.
585 doi:10.3389/fpsyt.2020.00104
586 43. Verkhratsky A, Matteoli M, Parpura V, Mothet JP, Zorec R. Astrocytes as
587 secretory cells of the central nervous system: idiosyncrasies of vesicular secretion.
588 *EMBO J*. Feb 1 2016;35(3):239-57. doi:10.15252/embj.201592705
589 44. Wong RW, Guillaud L. The role of epidermal growth factor and its receptors in
590 mammalian CNS. *Cytokine Growth Factor Rev*. Apr-Jun 2004;15(2-3):147-56.
591 doi:10.1016/j.cytogfr.2004.01.004
592 45. Kuhn HG, Winkler J, Kempermann G, Thal LJ, Gage FH. Epidermal growth
593 factor and fibroblast growth factor-2 have different effects on neural progenitors in the
594 adult rat brain. *J Neurosci*. Aug 1 1997;17(15):5820-9.
595 doi:10.1523/JNEUROSCI.17-15-05820.1997
596 46. Kuhn HG, Dickinson-Anson H, Gage FH. Neurogenesis in the dentate gyrus of
597 the adult rat: age-related decrease of neuronal progenitor proliferation. *J Neurosci*.
598 Mar 15 1996;16(6):2027-33. doi:10.1523/JNEUROSCI.16-06-02027.1996
599 47. Berger T, Lee H, Young AH, Aarsland D, Thuret S. Adult Hippocampal
600 Neurogenesis in Major Depressive Disorder and Alzheimer's Disease. *Trends Mol*
601 *Med*. Sep 2020;26(9):803-818. doi:10.1016/j.molmed.2020.03.010
602 48. Estrada-Reyes R, Quero-Chavez DB, Alarcon-Elizalde S, et al. Antidepressant
603 Low Doses of Ketamine and Melatonin in Combination Produce Additive
604 Neurogenesis in Human Olfactory Neuronal Precursors. *Molecules*. Sep 1
605 2022;27(17)doi:10.3390/molecules27175650

606 49. Stoll SW, Stuart PE, Swindell WR, et al. The EGF receptor ligand amphiregulin
607 controls cell division via FoxM1. *Oncogene*. Apr 21 2016;35(16):2075-86.
608 doi:10.1038/onc.2015.269
609 50. Wu J, Li S, Zhang Y. Research progress in role of exosomes exosomes in mental
610 disorders. *Zhong Nan Da Xue Xue Bao Yi Xue Ban*. May 28 2023;48(5):771-781. 外
611 泌体在精神障碍中作用的研究进展. doi:10.11817/j.issn.1672-7347.2023.220379
612 51. Morel L, Regan M, Higashimori H, et al. Neuronal exosomal miRNA-dependent
613 translational regulation of astroglial glutamate transporter GLT1. *J Biol Chem*. Mar 8
614 2013;288(10):7105-16. doi:10.1074/jbc.M112.410944
615 52. Guitart K, Loers G, Buck F, Bork U, Schachner M, Kleene R. Improvement of
616 neuronal cell survival by astrocyte-derived exosomes under hypoxic and ischemic
617 conditions depends on prion protein. *Glia*. Jun 2016;64(6):896-910.
618 doi:10.1002/glia.22963
619 53. Gusev A, Ko A, Shi H, et al. Integrative approaches for large-scale
620 transcriptome-wide association studies. *Nat Genet*. Mar 2016;48(3):245-52.
621 doi:10.1038/ng.3506
622
623

624 **Figure legends**



625

626 **Figure 1.** Comparisons of target protein concentrations in astrocyte-derived

627 extracellular vesicles (ADEVs) between treatment-resistant depression (TRD) and

628 healthy control (HC) group at baseline. Note: n.s.: not significant; *$p_{\text{false discovery rate (FDR)}}$

629 < 0.05; **$p_{\text{FDR}} < 0.01$; ***$p_{\text{FDR}} < 0.001$.

630



Figure 2. Changes of target protein concentrations in ADEVs between pre- and post-ECT in patients with TRD. Note: n.s.: not significant; *$p_{\text{false discovery rate (FDR)}} < 0.05$; **$p_{\text{FDR}} < 0.01$; ***$p_{\text{FDR}} < 0.001$.



Figure 3. Western blotting results of cell expriments. A-F: After 24 hours of intervention with ADEVs from patients with TRD and HCs in SH-SY5Y cells, the expression levels of doublecortin (DCX) protein in the HC group significantly increased compared to the TRD group. The phosphorylation levels of EGFR, PI3K, and Akt also significantly increased, while there was no significant difference in the phosphorylation levels of Erk between the two groups. G-L: After 24 hours of intervention with ADEVs from patients with TRD and HCs in SH-SY5Y cells, the expression levels of DCX protein in the HC group significantly increased compared to the TRD group. The phosphorylation levels of EGFR, PI3K, and Akt also significantly increased, while there was no significant difference in the phosphorylation levels of Erk between the two groups. Note: n.s.: not significant; $*p_{FDR} < 0.05$; $**p_{FDR} < 0.01$.

Table 1. Baseline comparisons of neurotrophic factors in ADEVs between TRD and HC groups

variable	HC group (EMM (95% CI))	TRD group (EMM (95% CI))	Difference (95% CI)	p	p_{FDR}
Main analysis: Normalized to CD81 ratio					
BDNF	0.0025 (0.0022 to 0.0029)	0.0012 (0.0009 to 0.0015)	-0.0013 (-0.0018 to -0.0009)	<0.001	<0.001
EGF	0.0011 (0.001 to 0.0012)	0.0003 (0.0002 to 0.0004)	-0.0008 (-0.0009 to -0.0006)	<0.001	<0.001
FGF-2	0.0039 (0.0032 to 0.0045)	0.0031 (0.0025 to 0.0037	-0.0008 (-0.0016 to 0.0001)	0.097	0.097
GDNF	0.0167 (0.0145 to 0.0189)	0.0121 (0.01 to 0.0141)	-0.0047 (-0.0076 to -0.0018)	0.002	0.004
NGF-β	0.0043 (0.0036 to 0.0050)	0.0035 (0.0028 to 0.0042)	-0.0008 (-0.0017 to 0.0001)	0.094	0.097
Sensitive analysis: Normalized to 1 ml plasma					
BDNF	9.84 (8.16 to 11.52)	8.65 (7.1 to 10.2)	-1.19 (-3.41 to 1.03)	0.298	0.298
EGF	3.98 (3.62 to 4.34)	2.01 (1.67 to 2.34)	-1.97 (-2.45 to -1.5)	<0.001	<0.001
FGF-2	13.94 (10.56 to 17.32)	21.39 (18.27 to 24.51)	7.45 (2.98 to 11.92)	0.002	0.002
GDNF	60.55 (53.47 to 67.64)	82.77 (76.24 to 89.31)	22.22 (12.85 to 31.59)	<0.001	<0.001
NGF-β	15.42 (11.71 to 19.13)	24.56 (21.14 to 27.98)	9.14 (4.23 to 14.05)	<0.001	0.001

Table 2. Changes of neurotrophic factors in ADEVs of TRD after ECTs.

Variable	Change from baseline (95% CI))	Cohen's *d* (95% CI))	*p*	p_{FDR}
Main analysis: Normalized to CD81 ratio				
BDNF	0.00001 (-0.00022 to 0.00024)	0.01 (-0.33 to 0.36)	0.934	0.934
EGF	0.00027 (0.00019 to 0.00036)	1.14 (0.69 to 1.57)	<0.001	<0.001
FGF-2	-0.00047 (-0.00118 to 0.00024)	-0.23 (-0.58 to 0.11)	0.189	0.321
GDNF	0.00066 (-0.00101 to 0.00233)	0.14 (-0.2 to 0.48)	0.424	0.53
NGF-β	-0.00048 (-0.00122 to 0.00026)	-0.23 (-0.58 to 0.12)	0.193	0.321
Sensitive analysis: Normalized to 1 ml plasma				
BDNF	-1.31 (-3.03 to 0.41)	-0.27 (-0.61 to 0.08)	0.131	0.131
EGF	1.2 (0.74 to 1.67)	0.91 (0.5 to 1.31)	<0.001	<0.001
FGF-2	-5.7 (-9.63 to -1.76)	-0.51 (-0.87 to -0.15)	0.006	0.007
GDNF	-9.15 (-15.48 to -2.82)	-0.51 (-0.87 to -0.15)	0.006	0.007
NGF-β	-6.74 (-11.19 to -2.29)	-0.54 (-0.9 to -0.17)	0.004	0.007

Supplementary materials



sFigure 1. Mendelian randomization framework.



sFigure 2. The spearman coefficient between EGF in ADEVs and the DCX in NDEVs.



sFigure 3. Results of Mendelian randomization study.



sFigure 4. Confirmation of ADEVs utilizing UC. A) The results of NTA show the diameter distribution of the EVs, which also corroborate with the prior knowledge of exosomes-like small EVs (peak diameter: 82.3 nm, concentration: $2.4*10^9$ particles/ml); B) The transmission electron microscopy image of ADEVs isolated from a health control, the image clearly shows the exosomes-like shape (orange arrows); C) Western blotting results of total EV (TEV), supernatant of TEV, and ADEV from one healthy control. Three exosomes markers, CD9, Alix, TSG 101, and an astrocyte marker glial fibrillary acidic protein (GFAP) was identified.

674

675 **sTable 1.** Baseline characteristics of included participants for clinical trial.

676

677 **sTable 2.** Genetic instruments for *EGF/EGFR* expression in brain tissues.

678

679 **sTable 3.** MELODI Presto results for *EGF/EGFR* genes and depression.

680

681 **Supplementary document:** Detailed Methods.

682


A
BDNF to CD81 Ratio in ADEVs
***
HC
TRD
B
EGF to CD81 Ratio in ADEVs
***
C
FGF−2 to CD81 Ratio in ADEVs
n.s.
D
GDNF to CD81 Ratio in ADEVs
**
E
NGF−β to CD81 Ratio in ADEVs
n.s.
F
sensitivity
1−specificity
Normalized to CD81 ratio
BDNF (AUC = 0.88 [0.81 to 0.96])
EGF (AUC = 0.99 [0.98 to 1.00])
FGF−2 (AUC = 0.63 [0.51 to 0.76])
GDNF (AUC = 0.65 [0.52 to 0.79])
NGF−β (AUC = 0.64 [0.51 to 0.77])
G
BDNF in ADEVs /Per 1 mL Plasma
n.s.
H
EGF in ADEVs /Per 1 mL Plasma
***
I
FGF−2 in ADEVs /Per 1 mL Plasma
**
J
GDNF in ADEVs /Per 1 mL Plasma
***
K
NGF−β in ADEVs /Per 1 mL Plasma
***
L
sensitivity
1−specificity
Normalized to 1 ml plasma
BDNF (AUC = 0.54 [0.41 to 0.67])
EGF (AUC = 0.93 [0.86 to 0.99])
FGF−2 (AUC = 0.69 [0.57 to 0.81])
GDNF (AUC = 0.77 [0.65 to 0.89])
NGF−β (AUC = 0.71 [0.59 to 0.82])

Changes after ECTs




TRD
HC
134 kDa
EGFR
134 kDa
p-EGFR
80 kDa
PI3K
80 kDa
p-PI3K
60 kDa
Akt
60 kDa
p-Akt
44/42 kDa
Erk1/2
44/42 kDa
p-Erk1/2
40 kDa
DCX
36 kDa
GAPDH
A
DCX/GAPDH
p-EGFR/EGFR
p-PI3K/PI3K
p-Akt/Akt
p-Erk/Erk
**
*
**
*
n.s.
HC
TRD
B
C
D
E
F
CTRL
EGF
G
H
I
J
K
L